Experience

Methods

• Evidence synthesis: systematic review, meta-analysis, meta-regression; frequentist and Bayesian.
• Technologies: drugs, surgical procedures, lifestyle interventions, diagnostic technologies.
• Epidemiology: burden of disease, population attributed risk, disease mapping.
• Data analysis: analysis of clinical trial data, analysis of routine data; frequentist and Bayesian.
• Statistical methods: Parametric and non-parametric regression, fixed and random effects models, hierarchical/multilevel modelling, spatial modelling, bootstrap and jack-knife, survival analysis, GLM, missing value analysis.
• Patient Reported Outcomes: time trade-off, standard gamble, conjoint analysis.
• Economic evaluation: decision trees, Markov models, discreet event simulations, probabilistic sensitivity analysis, expected value of information (EVI/EVPI).
• Costing of interventions: top-down, bottom-up, activity based costing.
• Drug pricing: based on expected evidence and competitive environment; optimisation models.
• Efficiency of providers: Data Envelopment Analysis.

Clinical areas

• Cardiovascular diseases: heart disease, stroke.
• Endocrinology: diabetes, glucose intolerance, diabetes education.
• Gastroenterology: GERD, bariatric surgery, upper GI bleeding, Crohn’s disease.
• Nephrology: Haemodialysis, peritoneal dialysis.
• Oncology: Breast cancer, colorectal cancer, lung cancer, oesophageal cancer, prostate cancer.
  
• Reproduction: In vitro fertilisation, preterm birth, contraception.
• Respiratory diseases: COPD, asthma.
• Genetic diseases: Fabry disease.

Research collaboration

• To broaden our methodological expertise and gain additional market access insights, we are involved in an ongoing collaboration with Swiss-based Gobal Market Access Solutions (GMA Solutions).